Samuel M. Rubinstein

2.0k total citations
43 papers, 631 citations indexed

About

Samuel M. Rubinstein is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Samuel M. Rubinstein has authored 43 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Oncology and 12 papers in Hematology. Recurrent topics in Samuel M. Rubinstein's work include Multiple Myeloma Research and Treatments (9 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Samuel M. Rubinstein is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Samuel M. Rubinstein collaborates with scholars based in United States, Australia and Taiwan. Samuel M. Rubinstein's co-authors include Jeremy L. Warner, Douglas B. Johnson, Andrzej P. Wojcieszynski, Peter Gabriel, Ellen Kim, Kevin T. Nead, Ryan David Nipp, Donald P. Lawrence, Krista M. Rubin and Anita Giobbie‐Hurder and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Samuel M. Rubinstein

40 papers receiving 627 citations

Peers

Countries citing papers authored by Samuel M. Rubinstein

Since Specialization

Citations

This map shows the geographic impact of Samuel M. Rubinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel M. Rubinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel M. Rubinstein more than expected).

Fields of papers citing papers by Samuel M. Rubinstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel M. Rubinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel M. Rubinstein. The network helps show where Samuel M. Rubinstein may publish in the future.

Co-authorship network of co-authors of Samuel M. Rubinstein

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel M. Rubinstein. A scholar is included among the top collaborators of Samuel M. Rubinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel M. Rubinstein. Samuel M. Rubinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Xi Zhou, Christopher D. Baggett, Sascha A. Tuchman, Christopher E. Jensen, Eben I. Lichtman, Samuel M. Rubinstein	1
2	Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial 2024 ·Blood ·(unknown), Rajshekhar Chakraborty, Al‐Ola Abdallah, Suzanne Lentzsch, (unknown), Douglas W. Sborov, Amandeep Godara, Brian McClune, (unknown), Samuel M. Rubinstein, Aaron M. Goodman, Ghulam Rehman Mohyuddin	0
3	Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review 2023 ·European Journal Of Haematology ·(unknown), Tomer Meirson, (unknown), Aaron M. Goodman, Rajshekhar Chakraborty, Douglas W. Sborov, Samuel M. Rubinstein, Ghulam Rehman Mohyuddin	2
4	Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study 2023 ·Cancers ·Rodney Dixon Dorand, Neil S. Zheng, Rajiv Agarwal, Robert J. Carroll, Samuel M. Rubinstein, Karen M. Winkfield, Wei‐Qi Wei, Jordan Berlin, Xiao‐Ou Shu	3
5	Geriatric assessment-guided interventions for older adults with multiple myeloma: A feasibility and acceptability study 2023 ·Journal of Geriatric Oncology ·Christopher E. Jensen, Allison M. Deal, Kirsten A. Nyrop, (unknown), (unknown), (unknown), Jordan Miller, Hyman B. Muss, Eben I. Lichtman, Samuel M. Rubinstein, Sascha A. Tuchman	3
6	Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma 2022 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Hillary Heiling, Allison M. Deal, Christopher E. Jensen, (unknown), Kirsten A. Nyrop, Eben I. Lichtman, Samuel M. Rubinstein, Shakira J. Grant, William A. Wood, Sascha A. Tuchman, Zev M. Nakamura	6
7	Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life 2022 ·The Oncologist ·Christopher E. Jensen, (unknown), Kirsten A. Nyrop, Allison M. Deal, (unknown), Shakira J. Grant, Hyman B. Muss, Eben I. Lichtman, Samuel M. Rubinstein, William A. Wood, (unknown), (unknown), Sascha A. Tuchman	6
8	Development of a bayesian toxo-equivalence model between docetaxel and paclitaxel 2022 ·iScience ·(unknown), Samuel M. Rubinstein, (unknown), Donna R. Rivera, Philip Walker, Qingxia Chen, Jeremy L. Warner	1
9	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 2022 ·JAMA Network Open ·Xuanyi Li, Alicia Beeghly‐Fadiel, Suresh K. Bhavnani, Hossein Tavana, Samuel M. Rubinstein, Bishal Gyawali, Irbaz Bin Riaz, (unknown), Jeremy L. Warner	4
10	How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis 2021 ·JACC CardioOncology ·Samuel M. Rubinstein, Keith Stockerl‐Goldstein	7
11	Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status 2021 ·Journal of Geriatric Oncology ·Christopher E. Jensen, (unknown), Kirsten A. Nyrop, Allison M. Deal, Hyman B. Muss, Eben I. Lichtman, Samuel M. Rubinstein, William A. Wood, (unknown), (unknown), Shakira J. Grant, Sascha A. Tuchman	18
12	Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis 2020 ·PLoS ONE ·Elaine C. Chen, Samuel M. Rubinstein, Cinque Soto, Robin Bombardi, Samuel B. Day, Luke Myers, (unknown), (unknown), Robert F. Cornell, James E. Crowe	1
13	Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis 2020 ·Blood ·Samuel M. Rubinstein, Ryan C. Lynch, Aakash Desai, Catherine Stratton, Alokkumar Jha, Ziad Bakouny, Andrew Schmidt, R. Alejandro Sica, Divaya Bhutani, Dimpy P. Shah, Sarah Wall, Gary H. Lyman, Nicole M. Kuderer, Matthias Weiss, Jeremy L. Warner, Keith Stockerl‐Goldstein, Ruben A. Mesa, Michael A. Thompson	7
14	Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia 2020 ·Frontiers in Oncology ·(unknown), Samuel M. Rubinstein, Robert F. Cornell	21
15	The Evolving Use of Electronic Health Records (EHR) for Research 2019 ·Seminars in Radiation Oncology ·Ellen Kim, Samuel M. Rubinstein, Kevin T. Nead, Andrzej P. Wojcieszynski, Peter Gabriel, Jeremy L. Warner	93
16	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy 2017 ·Pigment Cell & Melanoma Research ·Douglas B. Johnson, (unknown), Zachary R. Chalmers, Garrett M. Frampton, Siraj M. Ali, Samuel M. Rubinstein, David Fabrizio, Jeffrey S. Ross, Sohail Balasubramanian, Vincent A. Miller, Philip J. Stephens, Jeffrey A. Sosman, Christine M. Lovly	28
17	Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis 2017 ·Biology of Blood and Marrow Transplantation ·Oluchi Oke, Tarsheen Sethi, Stacey Goodman, Sharon Phillips, (unknown), Samuel M. Rubinstein, Beatrice P. Concepcion, (unknown), Madan Jagasia, Adetola A. Kassim, (unknown), Anthony Langone, Daniel J. Lenihan, (unknown), David Slosky, Robert F. Cornell	6
18	Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma 2016 ·Annals of Oncology ·Robba Rai, Jennifer L. McQuade, (unknown), (unknown), (unknown), Jeffrey A. Sosman, Kathryn E. Beckermann, Lauren E. Haydu, Serigne Lo, Samuel M. Rubinstein, Meredith McKean, Susan Matthew, Alexander Guminski, Matteo S. Carlino, Michael A. Davies, (unknown), Georgina V. Long, Alexander M. Menzies	14
19	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation 2016 ·Biology of Blood and Marrow Transplantation ·Zhuoyan Li, Samuel M. Rubinstein, Ramya Thota, Malvi Savani, Éolia Brissot, Bronwen E. Shaw, Navneet S. Majhail, Mohamad Mohty, Bipin N. Savani	37
20	EPR Oxygen Images Predict Tumor Control by a 50% Tumor Control Radiation Dose 2013 ·Cancer Research ·Martyna Elas, (unknown), (unknown), (unknown), (unknown), (unknown), Eugene D. Barth, Boris Epel, Samuel M. Rubinstein, Charles A. Pelizzari, Ralph R. Weichselbaum, Howard J. Halpern	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact